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Abstract: To tackle the growing problem of antibiotic resistance, it is essential to identify new
bioactive compounds that are effective against resistant microbes and safe to use. Natural products
and their derivatives are, and will continue to be, an important source of these molecules. Sea sponges
harbour a diverse microbiome that co-exists with the sponge, and these bacterial communities
produce a rich array of bioactive metabolites for protection and resource competition. For these
reasons, the sponge microbiota constitutes a potential source of clinically relevant natural products.
To date, efforts in bioprospecting for these compounds have focused predominantly on sponge
specimens isolated from shallow water, with much still to be learned about samples from the
deep sea. Here we report the isolation of a new Micromonospora strain, designated 28ISP2-46T,
recovered from the microbiome of a mid-Atlantic deep-sea sponge. Whole-genome sequencing
reveals the capacity of this bacterium to produce a diverse array of natural products, including
kosinostatin and isoquinocycline B, which exhibit both antibiotic and antitumour properties. Both
compounds were isolated from 28ISP2-46T fermentation broths and were found to be effective against
a plethora of multidrug-resistant clinical isolates. This study suggests that the marine production of
isoquinocyclines may be more widespread than previously supposed and demonstrates the value
of targeting the deep-sea sponge microbiome as a source of novel microbial life with exploitable
biosynthetic potential.
Keywords: antibiotic; deep sea; sea sponge; bioprospecting; natural product; secondary metabolites;
biosynthetic gene clusters; genome mining; nanopore sequencing
1. Introduction
Antibiotic resistance is emerging as a global crisis, with a growing number of bacterial
infections becoming harder to treat [1]. There has been no new, clinically viable class of
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antibiotic discovered since the 1980s [2]. According to the US Centre for Disease Control,
we are already in a post-antibiotic era: common infections and minor injuries are becoming
deadly, and routine medical procedures impossible to perform [3]. To tackle the emerging
problem of antibiotic resistance, the identification of new antibiotics that are safe and
effective against resistant microbes is of paramount importance [1].
Microbial natural products and their derivatives have, and will continue to be, an
important source of medically important compounds. Recent advances in molecular, ge-
netic and analytical methods are now enabling the rapid identification and characterisation
of new natural product antimicrobials from microorganisms, driving a renaissance in the
field [4,5]. One facet of this discovery effort is the exploitation of unsampled and extreme
ecological niches. This has led to a particular interest in the deep sea, meaning ocean depths
below ~1000 m, which are some of the least explored and most hostile environments on
Earth. Ambient conditions in the deep sea can include low temperature, light, and oxygen
content as well as high pressure and saline concentration. Microorganisms adapt to these
extreme environments through a variety of metabolic innovations. For this reason, marine
extremophiles are widely considered to be an important target for the discovery of novel
natural products.
One potential source of deep-sea natural products are the abundant and diverse
symbiotic microbial communities harboured by the sea sponges (phylum Porifera). This
microbiome can account for up to 40% of the mass of a sponge [6,7] and commonly
includes representatives of the Actinobacteria, which are famously versatile producers of
secondary metabolites. The discovery potential is illustrated by the fact that over 30% of
the ~15,000 unique marine natural products described to date have been isolated from
sponge samples [8]. However, this has largely been confined to specimens from shallow
waters and deep-sea sponges have been less well explored [9].
In recent studies we employed a remotely operated vehicle (ROV), deployed at depths
of 0.5–4 km to recover sponge samples from previously unexplored regions of the mid-
Atlantic seabed [10]. A subset of the microbiota of the sponges recovered during this
expedition have been isolated and screened for their ability to biosynthesise natural prod-
ucts with antimicrobial activities. A number of the microorganisms recovered have been
found capable of biosynthesising novel antimicrobial natural products [10]. Here we re-
port the identification and characterisation of one such strain, which we term 28ISP2-46T,
isolated from a sponge found 971 m below sea level. 16S rRNA gene and whole-genome
sequencing of strain 28ISP2-46T was consistent with its classification as a novel species of
the genus Micromonospora, for which the name Micromonospora ferruginea sp. nov. (NCTC
number: 14469T, DSMZ number: 111791T) is proposed. Interrogation of the genome se-
quence identified a plethora of natural product biosynthetic gene clusters, many of which
appear, based on bioinformatic analyses, to incorporate unusual biochemical features.
The antitumour antibiotics kosinostatin and isoquinocycline B, which both comprise an
anthracycline-like aglycon core coupled to a functionalised pyrrolopyrrole ring [11], could
be readily isolated from 28ISP2-46T fermentation broths. These compounds are shown
herein to possess antibiotic activity against a variety of pathogenic bacteria, including
Gram-positive, Gram-negative and multidrug-resistant strains, along with tumour cell line
cytotoxicity. This study serves to further highlight the importance of the deep-sea sponge
microbiome as a source of novel microbial life and natural product chemistry.
2. Results
2.1. Sponge Sample Collection and Processing
The Tracing Ocean Processes Using Corals and Sediments (TROPICS) research cruise
(RRS James Cook expedition JC094) collected samples of Porifera (sea sponge) from five
different sites across the equatorial Atlantic (Figure 1a). Sampling was executed between
0.5 and 4 km below the surface using a remotely operated vehicle (ROV) (Figure 1b) [10].
Once at the surface, samples were cryopreserved and transported to Bristol.
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Figure 1. (a) Map of the sampling areas (arrowed) from the JC094 research cruise in the mid-Atlantic Ocean (created using
ETOPO1 bathymetry). (b) The robotic arm of the remotely operated vehicle (ROV) used for collecting samples and one of
the samples collected.
Microbial culturing studies were performed using a demosponge sample (Supplemen-
tary Figure S1) collected at a sampling site in the eastern basin of the Atlantic around the
Knipovich Seamount. Bacterial cultures isolated from the sponge sample were screened for
antimicrobial activity [10], and bacteria able to inhibit the growth of any of the test strains
were then taken forward for compound extraction and identification.
2.2. Isolation of a Micromonospora Strain with Antibiotic Activity
Culture-based screening with an agar overlay assay identified a deep-sea bacterial
strain with antibiotic activity against multidrug-resistant Gram-positive bacteria such as
Staphylococcus aureus Mu50 (methicillin and vancomycin resistant) (Figure 2b), as well
as the Gram-negative pathogen Acinetobacter baumannii ATCC 19606. The strain was
recovered from ISP2 (+ASW) agar incubated at 28 ◦C after 10 weeks post-inoculation and
subsequently grew to confluence on ISP2 agar or in broth within 3 weeks. In lieu of detailed
taxonomic assignment, we initially designated this strain 28ISP2-46T according to our own
arbitrary numbering system, which indicates that the strain was isolated at 28 ◦C and was
the 46th colony to be isolated on ISP2 media. Visual inspection of colonies of 28ISP2-46T
on ISP2 agar revealed hard, wrinkled, rust-red colonies, turning to dark red/black upon
sporulation, with a ‘molar tooth’ appearance (Figure 2a). The presence of a slight, pink,
diffusible pigment was also observed. The strain is aerobic, Gram positive, non-motile and
mesophilic. Scanning electron microscopy (SEM) indicated that the substrate hyphae are
extensively branched and fragmented irregularly into rod-shaped, non-motile elements
(Figure 2c). After a longer growth period (3 weeks), the strain visually began sporulating
(dark red/black), and the SEM revealed these spores to be ovoid to spherical in shape,
slightly rough on their surface and approximately 1 µm in diameter once fully grown
(Figure 2d). 16S rRNA gene sequencing identified the species as belonging to the genus
Micromonospora (99%; accession number MW003705.1), within the class Actinobacteria
(Tables S2 and S3).
Mar. Drugs 2021, 19, 105 4 of 19
Figure 2. (a) Colonies of strain 28ISP2-46T grown on ISP2 agar for 3 weeks. (b) Antibiotic activity of 28ISP2-46T numbered
‘46’ against Staphylococcus aureus Mu50 in a soft agar overlay assay. (c) Scanning electron micrograph of cells of strain
28ISP2-46T after growth on LB agar for 7 days at 28 ◦C. (d) Scanning electron micrograph of cells and spores (indicated by
arrows) of strain 28ISP2-46T after growth on LB agar for 3 weeks at 28 ◦C.
2.3. Identification of Quinocycline Antibiotics
In an effort to establish the identity of the molecule(s) responsible for the observed
antimicrobial activity, 28ISP2-46T was cultured in 10 mL ISP2 broth for 3 weeks. Cells were
harvested by centrifugation, and the supernatant and pellet fractions extracted in ethyl
acetate. Supernatant fractions exhibited antibacterial activity (Figure S2). There was no
loss of activity in supernatant samples pretreated with Proteinase K, indicating that the
active molecule(s) was not a peptide (Figure S2).
For the isolation and characterisation of metabolites, it proved necessary to scale up
the fermentation of 28ISP2-46T to 2 L of culture volume. It has been previously established
that a higher yield of product can be obtained when the bacteria are grown in a less-rich
media [11]. So, for these large-scale fermentations, 28ISP2-46T was grown in 25% ISP2
with artificial sea water (ASW). The supernatant was extracted with ethyl acetate and
evaporated in vacuo to give a crude extract, which was subjected to LC–MS analysis
(Figure 3). The crude extract was further purified by HPLC to yield compounds 1 (~ 2 mg)
and 2 (~3 mg). Compound 1 was unstable and isomerised to 2 at room temperature. HR-MS
and NMR analysis identified compound 2 as isoquinocycline B (Figure 4, Supplementary
Figures S3–S7), previously isolated and identified from Streptomyces [12–15]. This was
further confirmed by comparing the NMR data of 2 with those of a standard sample
of isoquinocycline B, provided by Prof. Gong-Li Tang (Shanghai Institute of Organic
Chemistry, Chinese Academy of Sciences) (data not shown). Compound 1 was proposed to
be kosinostatin, although full characterisation was not possible as it was unstable.
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Figure 3. HPLC-ELSD chromatogram of the crude extract of Micromonospora sp. 28ISP2-46T.
Figure 4. Structures of the two quinocycline compounds: quinocycline B (‘kosinostatin’) (1) and
isoquinocycline B (2).
The two quinocycline antibiotics (1–2, Figure 4) are similar to anthracyclines and the
overall structure is composed of an aglycon core, a sugar moiety and a pyrrolopyrrole ring
(Figure 4) [12]. Compounds 1 and 2 have been shown to have antibiotic activity and to also
inhibit DNA topoisomerase IIα [14].
2.4. Biological Activities
The minimum inhibitory concentration (MIC90) of the purified compound (2) was deter-
mined against A. baumannii ATCC 17978, Pseudomonas aeruginosa ATCC 33359, Escherichia coli
BW25113, Klebsiella pneumoniae ATCC 10,031 and Staphylococcus aureus SH1000, along with
genetically modified strains to help ascertain any mechanisms of resistance (Table 1). These
GM strains included an efflux knockout (KO) strain of A. baumannii (CCD167h1.1), a
derivative of ATCC 17,978 with deletion of two efflux pumps (∆adeIJ, ∆A1S_3447-3446);
an efflux KO of P. aeruginosa (CCD047), a derivative of NCTC 11451 with deletion of four
efflux pumps (∆mexAB, ∆mexCD, ∆mexVW, ∆mexXY); an efflux KO of E. coli (CCD121a8), a
derivative of BW25113 with deletion of six efflux pumps (∆acrAB, ∆acrD, ∆emrAB, ∆macAB,
∆mdfA, ∆mdtK); and E. coli CCD181-1 (BW25113 imp4213), an increased membrane perme-
ability (IMP) strain (Table S1).
Isoquinocycline B (2) showed good antibiotic activity not only against the Gram-
positive strain S. aureus SH1000, but also the Gram-negative strains K. pneumoniae ATCC
10031 and A. baumannii ATCC 17978. However, there was no activity against the other
Gram-negative strains, except the efflux KO mutant strains, indicating that these strains are
unable to transport the compound out of the cell, and thus demonstrating the mechanism
of resistance of these strains.
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Table 1. MIC90 of isoquinocycline B (2), purified from strain 28ISP2-46T. Sitafloxacin was utilised as
a positive control. The experiment was performed twice (error values in parentheses are standard
error from the mean and are only shown for experiments where the MIC90 values from the two




A. baumannii ATCC 17978 25 0.0781
A. baumannii efflux KO a 1.563 <0.0195
P. aeruginosa ATCC 33359 >100.0 0.469 (±0.156)
P. aeruginosa efflux KO b 12.5 0.156
E. coli BW25113 >100.0 <0.0195
E. coli efflux KO c 9.375 (±3.125) <0.0195
E. coli IMP d <0.1953 <0.0195
K. pneumoniae ATCC 10031 12.5 <0.0195
S. aureus SH1000 1.562 0.117 (±0.039)
a A. baumannii CCD167h1.1, efflux KO (ATCC 17978 ∆adeIJ ∆A1S_3447-3446); b P. aeruginosa CCD047, efflux
KO (NCTC 11,451 ∆mexAB ∆mexCD ∆mexVW ∆mexXY); c E. coli CCD121a8, efflux KO (BW25113 ∆acrAB ∆acrD
∆emrAB ∆macAB ∆mdfA ∆mdtK); d E. coli CCD181-1, increased membrane permeability (BW25113 imp4213).
The in vitro cytotoxicity of isoquinocycline B (2) was tested against the human liver
cancer cell line HepG2 (Table 2). The compound exhibited relatively high activity against
this cell line, with a half inhibitory concentration (IC50) of 13.3 µM and 0% cell viability at
100 µM.
Table 2. Cytotoxicity assay of isoquinocycline B (2) against the HepG2 (ATCC HB-8065) cell line.
Thioridazine hydrochloride was utilised as a positive control.
Compound ID IC50 (µM) Cell Viability at 100 µM (%)
2 13.3 0.0
CONTROL 22.5 0.0
2.5. Genome Sequencing and Assembly
Highly accurate short-read sequencing (Illumina MiSeq) was combined with less
accurate long-read sequencing (Nanopore MinION) to produce a high-quality hybrid
assembly of the genome of 28ISP2-46T. The Unicycler [16] software was used to produce
a hybrid assembly of the 28ISP2-46T genome (Table 3). This generated an Illumina-only
assembly using the SPAdes assembler [17] and assessed the number of connections between
contigs on the assembly graph. The less-accurate longer reads from Nanopore sequencing
were used to resolve any repeat regions, eliminating all connections to produce a single
contig of 6.64 Mb (Table 3). The average coverage was 290×, which was consistent across
the assembly, and 98.5% of the Illumina reads mapped back to the assembly with an error
rate of 0.44%. The complete genome sequence of strain 28ISP2-46T has been deposited
at DDBJ/ENA/GenBank under the accession number CP059322. The annotated genome
features are listed in Supplementary Table S4 and the Clusters of Orthologous Groups
analysis is presented in Supplementary Figure S9.
An in silico method was used to compare the genome of strain 28ISP2-46T with those
of other Micromonospora species. The Genome-to-Genome Distance Calculator (GGDC) [18]
was employed to infer whole-genome distances which mimic DNA–DNA hybridisation
(DDH), thus reporting DDH values and the probability that two bacteria belong to the
same species. GGDC was used to align the genome assembly of strain 28ISP2-46T against
all 152 sequenced Micromonospora genomes on the NCBI database. The closest relatives are
Micromonospora humi (DDH = 49.2, %GC difference = 0.12, probability same species = 17%)
and Micromonospora sediminicola (DDH = 40.2, %GC difference = 0.09, probability same
species = 3%). A DDH value below 70% indicates that two strains belong to different
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species, supporting the proposal that strain 28ISP2-46T represents a novel species of the
genus Micromonospora.
Table 3. Summary statistics for assemblies from Illumina only, Oxford Nanopore only and Illu-
mina/Oxford Nanopore hybrid genome sequencing of strain 28ISP2-46T.
Illumina Only Nanopore Only Illumina/NanoporeAssembly
Number of contigs 637 196 1
Total length (Mb) 6.62 8.06 6.64
Shortest contig 123 nt 1.03 kb 6.64 Mb
Largest contig 1.36 kb 6.70 Mb 6.64 Mb
Average coverage a 36.3 313 290
Coverage std dev 19.9 137 113
N50 (kb) 22.3 6700 6640
L50 92 1 1
Mapped reads 98.5% 99.6% 98.5%
Error rate 1.27% 10.8% 0.44%
GC content 72.4% 72.3% 72.5%
a Coverage is average reads per base, calculated from an alignment of the trimmed reads (reads trimmed with
TrimGalore, aligned against the assembly contigs using Bowtie2). Average coverage is the unweighted average of
the coverage of each contig separately.
The Type Strain Genome Server (TYGS) was used to generate a phylogenetic tree
for strain 28ISP2-46T (Figure 5), by using a whole-genome BLAST distance phylogeny
approach [19].
Figure 5. Phylogenetic tree for strain 28ISP2-46T and the other group IA Micromonospora species generated using the TYGS
and drawn with iTOL. The tree was constructed using FastME 2.1.6.1 [20] from GBDP distances calculated from genome
sequences. The branch lengths are scaled in terms of GBDP distance formula d5. The numbers above branches are GBDP
pseudo-bootstrap support values from 100 replications, with an average branch support of 98.4% and a delta statistic of
0.135. The tree was rooted using Micromonospora pallida as the outgroup.
The Antibiotics and Secondary Metabolites Analysis Shell (AntiSMASH) [21] was
used to identify putative biosynthetic genes, organise them into predicted clusters, and
find their closest known relatives to predict the natural products of the clusters within the
genome of 28ISP2-46T. AntiSMASH identified 19 putative clusters in the draft genome
including a candidate gene cluster for kosinostatin biosynthesis (Table 4).
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Table 4. Biosynthetic gene clusters identified in the genome of strain 28ISP2-46T using AntiSMASH.
Region Type Cluster Size(kb)
Most Similar Known
Cluster
Strain of Most Similar
Known Cluster Similarity
a
1 T3PKS 40.6 Alkyl-O-dihydrogeranyl-methoxyhydroquinones Actinoplanes missouriensis 431 71%
2 Terpene 19.8 Isorenieratene Streptomyces argillaceus 25%
3 Terpene 16.8 Phosphonoglycans Glycomyces sp. NRRL B-16210 3%
4 NAGGN 14.7 No similar cluster
5 NRPS, T1PKS 61.7 Bleomycin Streptomyces verticillus 6%
6 Lanthipeptide 21.5 No similar cluster
7 NRPS, T1PKS 66.3 Nostopeptolide Nostoc sp. GSV224 25%
8 Lanthipeptide 21.6 SapB Streptomyces coelicolor A3(2) 75%
9 T1PKS, NRPS-like 214 Rifamycin Salinispora arenicola CNS-205 38%
10 NRPS, arylpolyene 84.8 Kedarcidin Streptoalloteichus sp. ATCC53650 13%
11 Terpene 19.3 Nocathiacin Nocardia sp. ATCC 202099 4%
12 T2PKS 71.2 Formicamycins A-M Streptomyces sp. KY5 13%
13 NRPS 49.1 Azicemicin Kibdelosporangium sp.MJ126-NF4 13%





51.0 Lobosamide Micromonospora sp.RL09-050-HVF-A 13%





158 Kosinostatin Micromonospora sp. TP-A0468 77%
18 Bacteriocin 10.8 Lymphostin Salinispora tropica CNB-440 33%
19 Terpene 21.0 No similar cluster
a The percentage of genes in the cluster with homologues in the ‘most similar known cluster’.
2.6. Quinocycline-Producing Gene Cluster
The ‘kosinostatin’ biosynthetic gene cluster (BGC) reported for strain 28ISP2-46T
(Table 4) is only the second confirmed from a quinocycline-producing strain. The first
was identified from Micromonospora sp. TP-A0468, which was shown to produce both 1,
quinocycline B (‘kosinostatin’), and 2, isoquinocycline B, despite the irreversible isomerisa-
tion of 1 to 2 at room temperature [12,14]. The BGC from 28ISP2-46T can be compared with
that of Micromonospora sp. TP-A0468 [22] to better define the BGC boundaries. AntiSMASH
defined the two BGCs as 77% similar based on gene conservation (Table 4) and as indicated
in Figure 6, the two BGCs are closely related. Ma et al. defined eight groups of genes in
the Micromonospora sp. TP-A0468 BGC, the predicted functions of which are shown in
Table 5 [22].
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Figure 6. (a) ClusterBLAST [21] hits for the kosinostatin cluster. Homologues of kst genes are coloured as follows: kstA genes
red, kstB genes yellow, kstC genes green, kstD genes blue, kstRg genes black, kstRs genes white, and genes uninvolved in
kosinostatin biosynthesis grey. A black line at the end of a cluster indicates that it is close to the end of a contig. Gene sizes not
to scale. The NCBI protein IDs for first and last coloured genes of each cluster are as follows: Micromonospora sp. TP-A0468
AFJ52719.1 and AFJ52701.1; Micromonospora sp. 28ISP2-46T QLQ36639.1 and QLQ36600.1; N. valliformis WP_017579213.1 and
WP_017579258.1; N. alkaliphila WP_017604198.1 and WP_017604153.1; Streptomyces sp. SM8 PKA38649.1 and PKA38729.1;
Streptomyces sp. ScaeMP-6W SCE31237.1 and SCE31955.1; A. bangkokensis OLR89622.1 and OLR89598.1; M. haikouensis
SCF11188.1 and SCF11278.1. (b) The same gene clusters rearranged for ease of comparison. Coloured as 6a.
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Table 5. The predicted functions for the groups of kosinostatin biosynthetic genes as defined by Ma et al. [22].
Gene Group Predicted Function Colour in Figure 6
kstA Synthesise the anthracycline and modify its rings. Red
kstB Load nicotinic acid and convert it to a pyrrole. Yellow
kstC Convert the pyrrole and phosphoribosyl pyrophosphate to the pyrrolopyrrole. Green
kstD Synthesise the branched deoxy-octose and attach it to the anthracycline. Blue
kstRg Transcription factors that control the expression of the BGC. Black
kstRs Provide self-resistance to kosinostatin. White
kstU Not involved in kosinostatin biosynthesis. Grey
Relative to the Micromonospora sp. TP-A0468 BGC, six ORFs are missing in strain
28ISP2-46T. There are no homologs of kstU1, kstRg3, kstU2, kstU3, kstRg4, or kstA14. KstU1
and KstU2 are hypothetical proteins with no putative conserved domains in the BLAST
database. KstRg3 and KstRg4 were predicted to be transcription factors [22]. Therefore,
the two producer strains may have evolved different regulatory mechanisms for the
production of the quinocyclines, or these genes may not act on either ‘kosinostatin’ cluster.
Ma et al. [22] identified ORF KstRg4 and included it in their ‘kosinostatin’ Minimum
Information about a Biosynthetic Gene (MiBIG) cluster. However, this putative gene
could not be found in the Micromonospora sp. TP-A0468 kosinostatin BGC sequence that
was deposited in the NCBI database. KstA14 was annotated as a dehydrogenase by
Ma et al. [22] because a weakly related gene from the zebrafish Danio rerio was annotated
with this function. This BLAST search was repeated, but a related gene from D. rerio could
not be found and all of the sequences returned were hypothetical proteins. Aligning the
KstA14 deduced amino acid sequence with all of the translated ORFs in the genome of strain
28ISP2-46T did not return any related ORFs. KstA14 does not have any putative conserved
domains in the BLAST database, and because it is not conserved between the two clusters,
it is unlikely to be involved in kosinostatin biosynthesis. Ma et al. predicted that KstA14
catalyses an auxiliary reaction in the biosynthesis of the kosinostatin anthracycline [22],
but this reaction could be catalysed by another KstA protein.
The major difference between the two BGCs is the absence of kstB7 in the strain
28ISP2-46T cluster. Ma et al. used kstB7 to define one boundary of the TP-A0468 BGC
because a ∆kstB7 strain had reduced kosinostatin production [22]. It was predicted that
KstB7, which has homology to a trypsin-like serine protease, removes a formyl group from
a pyrrole precursor (Figure S8). None of the putative peptidases near the strain 28ISP2-46T
kst BGC show significant similarity to kstB7 and are all outside the cluster. Aligning the
kstB7 nucleotide sequence with the entire strain 28ISP2-46T genome returns a homologue
with 81% identity, but this gene is nearly 1 Mb removed from the kosinostatin cluster.
Therefore, it seems unlikely that KstB7 is involved in kosinostatin biosynthesis, and the
deformylation reaction may be catalysed by an enzyme outside of the BGC or happen
spontaneously.
ClusterBLAST [21] was used to identify BGCs with similarity to the 28ISP2-46T kosi-
nostatin cluster (Figure 6a). The boundaries of the BGCs were identified by ClusterBLAST
and the ORFs were aligned to those of the TP-A0468 cluster to find kst gene homologues.
As indicated in Figure 6b, Nocardiopsis valliformis, Nocardiopsis alkaliphila, Streptomyces
sp. SM8 and Streptomyces sp. ScaeMP-6W have almost complete kosinostatin BGCs.
Actinokineospora bangkokensis may also have a complete kosinostatin BGC, although the
cluster is interrupted by the end of a contig (Figure 6a). None of these strains have yet been
reported to produce kosinostatin. It is notable that these species also lack the six genes
missing from strain 28ISP2-46T, implying that these are not necessary for kosinostatin
biosynthesis. The genome of Micromonospora haikouensis has homologues of all of the genes
downstream of the TP-A0468 cluster as well as of kstB7, which suggests that kstB7 is part of
a nearby cluster that includes a polyketide synthase. It also has homologues of some kstRs
and kstRg genes and kstD2, but no other kst homologues within twenty ORFs of the BGC.
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This could indicate that Micromonospora haikouensis once had a kosinostatin cluster which
has since been deleted.
2.7. Genome Comparison of Strain 28ISP2-46T with Other Micromonospora Species
Carro et al. [23] classified the Micromonospora species into five groups based on their
whole-genome sequences. M. humi, the closest relative of strain 28ISP2-46T, belongs to sub-
group Ia, which also includes M. aurantiaca, M. auratinigra, M. chalcea, M. chaiyaphumensis,
M. chersina, M. marina, M. sediminicola, and M. tulbaghiae. The genomes of these species
were analysed using antiSMASH to identify BGCs unique to strain 28ISP2-46T that may
be of special interest for genome mining (Table S3). Some of the predicted BGCs from the
genome of 28ISP2-46T are present in all of the other strains in group Ia, but some are in
only a few others and two are unique to strain 28ISP2-46T, including a cluster with 63%
similarity to the feglymycin BGC and the kosinostatin BGC. These observations indicate
that none of the most closely related strains to strain 28ISP2-46T produce kosinostatin and
it is unique within the group.
3. Discussion
In this study, we report the identification of a novel bacterial strain (28ISP2-46T) within
the class Actinobacteria from a deep-sea sponge, harvested from a depth of 971 m in the
mid-Atlantic Ocean. The strain was screened for antibiotic activity against a variety of
pathogenic bacterial strains and was shown to have antibiotic activity on agar against
predominantly Gram-positive species. Subsequently, two quinocycline compounds were
isolated from the growth medium of this strain, which were identified as the known
compounds quinocycline B (kosinostatin) (1) and the corresponding diastereoisomer iso-
quinocycline B (2) [12–15]. Based on the compounds identified and genome sequencing,
strain 28ISP2-46T is clearly distinct from other closely related type strains. Thus, it is pro-
posed that strain 28ISP2-46T is assigned to a novel species within the genus Micromonospora,
for which the name Micromonospora ferruginea sp. nov. is proposed. The type strain is
28ISP2-46T.
Quinocycline antibiotics have been identified in a number of different Streptomyces
strains over the past 60 years [12–15,24]. The structures of the compounds were eventually
fully solved in 2002 by Igarashi et al. [12], revealing an unusual glycosylated anthraquinoid
tetracycle with a pyrrolopyrrole ring spirally conjugated to the aglycon core. The same
study [12] supports our own observations of the reported spontaneous isomerisation of
quinocycline B (compound 1) into isoquinocyclin B (compound 2). Although attempts
have been made to chemically synthesise the quinocyclines, only synthesis of the branched
octose [25], pyrrolopyrrole substructure [26,27] and intermediate lactone [28] have so far
been achieved. Thus, biosynthesis provides the only current route to these compounds and
the insights gained here could facilitate strain engineering to enhance this production.
Isoquinocycline B (2) exhibited antibiotic activity against Gram-positive strain S. aureus
SH1000, as well as the Gram-negative strains K. pneumoniae ATCC 10,031 and A. baumannii
ATCC 17978. Experiments using knockout strains suggested that resistance in other Gram-
negative strains was mediated by efflux. Isoquinocycline B was also toxic to the HepG2 liver
cancer cell line, in agreement with the anticancer properties of kosinostatin highlighted by
Igarashi et al. [29]. The mechanism of cytotoxicity is indicated to be by inhibition of DNA
topoisomerase [14], similar to other DNA intercalators such as the aromatic polyketides
daunorubicin and doxorubicin, which have a similar anthracycline core [30].
It is increasingly possible to routinely assemble genomes that are highly contiguous
and accurate [31]. This is desirable because a more contiguous genome is easier to mine for
biosynthetic gene clusters. The hybrid assembly performed here using Nanopore MinION
and Illumina MiSeq data generated an accurate genome of strain 28ISP2-46T into a single
contig. The coverage was high and consistent across the assembly.
Strain 28ISP2-46T has considerable potential for the production of natural products,
with 19 putative secondary metabolite-producing gene clusters identified in the genome
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by AntiSMASH. One of the identified BGCs had a 77% similarity to the kosinostatin-
producing biosynthetic gene cluster from Micromonospora sp. TPA0468 [22], indicating
that it is the potential gene cluster used to produce the quinocycline molecules (1 and
2) purified from the growth media. It is promising that the other 18 biosynthetic gene
clusters identified might also produce compounds either in low quantities compared to 1
and 2, or under different conditions. Work will continue to mine these clusters, particularly
those with low sequence similarity to known clusters, for novel, antimicrobial compounds.
Recently, Zhou et al. (2019) [32] forced the production of a different secondary metabolite
in Micromonospora sp. TP-A0468 by deletion of the kosinostatin-producing cluster. Cloning
of the unknown gene clusters of strain 28ISP2-46T into heterologous expression strains
could also yield production of other secondary metabolites.
Analysis of the genome by the Genome-to-Genome Distance Calculator (GGDC)
and the Type Strain Genome Server (TYGS) reveals that strain 28ISP2-46T is a novel
species of the genus Micromonospora. Despite there being no whole-genome sequence of
Micromonospora sp. TP-A0468 published, the low similarity of the kosinosatin-producing
gene cluster of TP-A0468 with the predicted cluster of the strain 28ISP2-46T and visual
comparison of bacterial colonies on the same type of agar [14] demonstrates these strains
are not identical. The gene discrepancies between the BGCs of the two strains include the
absence of seven predicted genes in the 28ISP2-46T cluster, indicating that the previous
cluster gene annotation of TP-A0468 was not accurate. In particular, the absence of the
predicted gene for the trypsin-like serine protease KstB7 indicates that the predicted de-
formylation reaction of the kosinostatin precursor [22] (Figure S8) is likely catalysed by
another, unknown enzyme or happens spontaneously. Comparison with other possible
kosinostatin-producing BGCs from other strains supports the case that these genes are
probably not involved in kosinostatin biosynthesis. These other strains of bacteria that have
BGCs homologous to the kosinostatin-producing clusters from both Micromonospora sp.
TP-A0468 and the strain 28ISP2-46T (Figure 6) have not yet been shown to produce kosino-
statin. This is despite research that has indicated that most of these strains do produce at
least one form of anti-infective compound [33–36], demonstrating that the kst BGCs may
be ‘silent’ and could be activated to produce the kosinostatin under the right conditions.
According to the closest relatives of strain 28ISP2-46T it is part of the Micromonospora
group Ia. The species within this group share a number of homologous BGCs. However,
only 28ISP2-46T carries BGCs that are homologous to those that produce kosinostatin and
feglymicin. This indicates that the production of kosinostatin is unique to this strain within
group Ia. Feglymicin is a 13mer peptide antibiotic originally isolated from Streptomyces sp.
DSM 11,171 [37], which is an inhibitor of enzymes involved in peptidoglycan biosynthe-
sis [38]. 28ISP2-46T has a BGC with a 63% similarity to the feglymicin BGC, showing that
this strain may have the potential to produce this, or a similar, antibiotic compound.
In conclusion, here we report the identification and characterisation of a novel species
of the genus Micromonospora, which possesses the capacity to biosynthesise a diverse array
of natural products, including the anticancer antibiotics kosinostatin (1) and isoquinocy-
cline B (2). Isoquinocycline B (2), the more stable isomer of kosinostatin (1), was shown
herein to be active against a diverse panel of pathogenic bacteria, including multidrug-
resistant clinical isolates. This study can be considered a proof of concept, demonstrating
the value of bioprospecting approaches that target deep-sea sponge microbiota. We propose
that microorganisms from the deep sea represent an underexploited resource in the quest
to identify new natural product based antimicrobial lead compounds.
Description of ‘Micromonospora ferruginea’ sp. nov.
The novel strain 28ISP2-46T will be hereafter known as Micromonospora ferruginea sp. nov.
Micromonospora ferruginea: fer.ru.gi′ne.a. L. fem. adj. ferruginea, of the colour of iron
rust, dark red, referring to the colour of the colonies growing on ISP2 media.
M. ferruginea sp. nov. is an aerobic, Gram-positive, non-motile, mesophilic actino-
mycete that forms hard, rust-red-coloured colonies on ISP2 agar. It produces a peach-pink
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diffusible pigment, particularly visible on pale-coloured media. Substrate hyphae are
extensively branched and fragmented irregularly into rod-shaped, non-motile elements. It
produces spores that are ovoid to spherical, slightly rough, non-motile, and approximately
1 µm in diameter once fully grown. Growth of the strain is between 20 and 37 ◦C, between
pH 5 and 9, and in the presence of up to 4% NaCl on unbuffered Luria–Bertani agar. The
strain grows optimally at 28 ◦C, at pH 7, and in the presence of 0% NaCl. The genome
size of the type strain is 6.64 Mb and its DNA G+C content is 72.5 mol %. The strain was
isolated from a deep-sea sponge from the Knipovich Seamount in the Atlantic Ocean. The
type strain is 28ISP2-46T (NCTC number: 14469T, DSMZ number: 111791T).
4. Materials and Methods
4.1. Collection of Sponge Samples
Sponge samples were collected as part of a research cruise in the equatorial Atlantic;
the Tracing Ocean Processes Using Corals and Sediments (TROPICS) expedition JC094,
(13 October 2013–30 November 2013). Five locations were selected for sampling: from east
to west, the Carter and Knipovich seamounts in the eastern basin, the Vema fracture zone
at the Mid-Atlantic Ridge and the Vayda and Gramberg seamounts in the western basin.
The sponges were subsampled in a controlled-temperature (4 ◦C) laboratory on board the
ship before flash freezing them for storage at −80 ◦C. The sponge used for the current
study was collected at a depth of 971 m, from the Knipovich seamount in the eastern basin
of the Atlantic Ocean (5◦ 37.5038′ N, 26◦ 57.4780′ W). It was taxonomically assigned to
the Class Demospongiae by microscopic identification of sigma-C microscleres during the
research cruise (Supplementary Figure S1).
4.2. Sponge Processing and Isolation of Bacterial Strains
The sponge sample was prepared and homogenised as described by this group in
Williams et al. 2020 [10]. The sponge homogenate was serially diluted (10−1 to 10−4) with
sterile artificial sea water (ASW; Crystal Sea Marine Mix, Marine Enterprise International,
made to the manufacturer’s instructions) and spread onto a variety of agar types [10], in du-
plicate. All agar was made with ASW and supplemented with cycloheximide (10 µg/mL)
to inhibit fungal growth. To maximise recovery of environmental isolates, media included
sodium pyruvate (100 µg/mL) [39], trace metal solution (Trace Metal A5 with co, Sigma-
Aldrich; 1 mL/L) and Basal Medium Eagle concentrated solution (BME, Sigma Aldrich;
1 mL/L) [40]. Nalidixic acid (30 mg/mL) was also added to some media to inhibit the
growth of Gram-negative bacteria. Duplicate plates were incubated at 4 and 28 ◦C for
4–10 weeks. A large number of colonies with a wide variety of morphologies were picked
and streaked onto fresh agar of the same type to grow as a monoculture in the same isolation
temperature. The axenic strains were then directly stocked from the agar plate into Mi-
croorganism Preservation System Protect Cryotubes (Technical Service Consultants Ltd.,
Heywood, UK) and stored at −70 ◦C.
4.3. 16S rRNA Gene Sequencing of Strain 28ISP2-46T
Genomic DNA from strain 28ISP2-46T was purified with a GenElute Bacterial Genomic
DNA Kit (Sigma) following the manufacturer’s protocol. A sample of the resulting DNA
solution (1 µL) was mixed with 12.5 µL of CloneAmp HiFi PCR premix (ClonTech), 9.5 µL
of ddH2O, and 1 µL each of the primers 8F (AGAGTTTGATCCTGGCTCAG) and rP2
(ACGGCTACCTTGTTACGACTT) at 10 µM. The following thermocycler program was
used: initial denaturation (1 cycle): 10 min at 95 ◦C. Amplification (35 cycles): 1 min at
95 ◦C, 1 min at 58 ◦C, 1.5 min at 72 ◦C. Final extension (1 cycle): 10 min at 72 ◦C. For
negative controls, ddH2O was used. The presence of single bands was confirmed using
gel electrophoresis and PCR products were purified with a QIAquick PCR cleanup kit
(Qiagen). Sequencing (Eurofins Genomics) using the 8F and rP2 primers was performed to
identify the strains.
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4.4. Cultivation Conditions of 28ISP2-46T
The ability of strain 28ISP2-46T to grow under a range of conditions was investigated
by culturing the strain on a range of Luria–Bertani (LB) agar with differing compositions.
The pH of unbuffered LB agar was adjusted between 5 and 12 at increments of 1 pH unit,
and the NaCl content prepared between 0 and 12% w/v at 2% increments. The strain was
incubated on these media at 28 ◦C. The strain was also incubated on standard LB agar at
4, 15, 20, 28, 34, 37, and 45 ◦C. It was additionally grown anaerobically on standard LB
agar at 28 ◦C in candle jars with AnaeroGen 2.5 L bags (Thermo Scientific). In all cases, the
cultures were incubated for four weeks and each test was repeated in triplicate.
4.5. Scanning Electron Microscopy of 28ISP2-46T
The strain 28ISP2-46T was cultured on sterile 0.2 µm cellulose acetate filters (Sartorius
Stedim Biotech) on LB agar (0% NaCl) for 1 week, and for an additional 2 weeks for spore
identification. The filter paper was then peeled off and the specimens prepared for scanning
electron microscopy (SEM). The filters were washed for 10–20 s in 0.1 M cacodylate buffer
prior to fixing in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3) for 1 h. They were
then washed in cacodylate buffer and fixed in 1% osmium tetroxide in 0.1 M cacodylate
buffer for 30 min. After buffer and dH2O washes, the membranes were dehydrated with
increasing ethanol concentrations and loaded in 100% ethanol onto the critical point dryer
(Leica EM CPD300) to dry. They were then sputter coated with Au/Pd using an Emitech
K575X coating unit and imaged in a Quanta 200 Field Emission SEM (FEI, Thermo Fisher,
Hillsboro, OR, USA).
4.6. Soft Agar Overlay Antibiotic Activity Assay
Strain 28ISP2-46T was inoculated as a small circle onto ISP2 agar (0.4% yeast extract,
1% malt extract, 0.4% dextrose, 3.3% ASW, 1.5% agar) and incubated at 28 ◦C for 15 days.
Bacterial strains Staphylococcus aureus Newman, S. aureus Mu50, Pseudomonas aeruginosa
PA01, Escherichia coli BW55113, Klebsiella pneumoniae NCTC 5055 and Acinetobacter baumannii
ATCC 19,606 were grown in Mueller–Hinton broth (Sigma), at 37 ◦C, for 16 h. Each culture
was suspended at OD600 = 0.01 in warm (42 ◦C), soft Mueller–Hinton agar (0.75% agar)
and 10 mL of this overlay agar poured onto the circle of 28ISP2-46T. Plates were incubated
at 37 ◦C for 16 h, at which point a zone of inhibition was clearly visible.
4.7. Small-Volume Liquid Culture Antibiotic Activity Assay of 28ISP2-46
Strain 28ISP2-46T was cultured in ISP2 broth (20 mL; 0.4% yeast extract, 1% malt
extract, 0.4% dextrose, 3.3% ASW), for 15 days, at 28 ◦C, 180 rpm. The cells were harvested
from 10 mL of culture using centrifugation. The supernatant (10 mL) was extracted with
ethyl acetate (1:1, v/v). The remaining cell pellet was extracted with 1 mL methanol,
vortexed for 1 min, and cell debris was removed by centrifugation at 13,000× g, 5 min. An
aliquot of supernatant (0.5 mL) was treated with proteinase K (100 µg/mL, 1.5 h, 37 ◦C).
All the samples were tested for antibiotic activity against the human pathogen S. aureus
Newman, a strain that has been widely used as a model for staphylococcal infection.
S. aureus Newman was cultured in Mueller–Hinton broth, 37 ◦C, for 16 h, then diluted in
fresh Mueller–Hinton broth to OD600 = 0.1 and spread (25 µL) on a Mueller–Hinton agar
plate. Wells were punched in the agar using the base of a sterile 1 mL pipette tip. Each
of the extracts (50 µL) was added to a well. The activity of the extracts was compared to
controls of a disk containing 5 µg of levofloxacin and a well containing 10 µg vancomycin.
The plates were incubated at 37 ◦C for 16 h, at which point zones of inhibition could be
observed.
4.8. Analysis and Identification of the Active Compound
Strain 28ISP2-46T was cultured in 25% ISP2 broth (×2 1 L) in Erlenmayer 2 L flasks for
15 days, at 28 ◦C, 180 rpm. The culture broth was extracted using ethyl acetate (1:1, v/9-)
three times and the combined extracts were dried over anhydrous MgSO4 and evaporated
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in vacuo to give a crude extract, which was subjected to liquid chromatography mass
spectrometry (LC–MS) analysis (Supplementary Section S1).
4.9. Antimicrobial Susceptibility Testing of the Active Compound
Antimicrobial susceptibility testing (AST) employed A. baumannii ATCC 17978, A. baumannii
CCD167h1.1, a derivative of ATCC 17,978 with deletion of two efflux pumps (∆adeIJ
∆A1S_3447-3446), E. coli BW25113, E. coli CCD121a8, a derivative of BW25113 with deletion
of six efflux pumps (∆acrAB ∆acrD ∆emrAB ∆macAB ∆mdfA ∆mdtK), E. coli CCD181-1
(BW25113 imp4213) with increased membrane permeability, K. pneumoniae ATCC 10031,
P. aeruginosa ATCC 33359, P. aeruginosa CCD047, a derivative of NCTC 11,451 with deletion
of four efflux pumps (∆mexAB, ∆mexCD, ∆mexVW, ∆mexXY) and S. aureus SH1000. AST
was based on the guidelines described in the Clinical and Laboratory Standards Insti-
tute (CLSI) as follows. Compound 2 and the control antibiotic sitafloxacin were diluted
in DMSO and stored at room temperature. Working stocks were prepared by making
10-point, 2-fold serial dilutions in DMSO at 50× the desired final concentration and 4 µL of
diluted samples were added to wells of a 96-well microtiter plate (Greiner Bio-One). Final
concentration ranges were 0.2 to 200 µM for the novel compounds and 0.02 to 10 µM for
sitafloxacin with two columns of the 96-well plates reserved for the growth control and the
negative control containing only cation-adjusted Mueller–Hinton broth (CAMHB).
Bacterial strains were streaked from frozen stocks onto Mueller–Hinton agar (MHA) to
obtain individual colonies. Overnight cultures were prepared by suspending 3–4 colonies
in CAMHB and incubating statically at 37 ◦C. Overnight cultures were diluted 1:100 in
CAMHB except for E. coli BW25113 (1:1000) and BW25113 imp4213 (1:10) and incubated at
37 ◦C for 1 h. Cultures were then diluted 1:100 in prewarmed CAMHB and microtitre plates
inoculated with 196 µL per well (final inoculum ~105 CFU/mL). After inoculation, plates
were covered with transparent seals (Greiner Bio-One) or, for A. baumannii, breathable seals
(Sigma Aldrich) and incubated at 37 ◦C for 20–24 h. OD600 was read (Perkin Elmer EnVision
Microplate Reader) and the minimum inhibitory concentrations (MICs) determined as the
minimum concentration of compound required to reduce OD600 by 90% as compared to
no-compound controls.
4.10. Cytotoxicity Assay
Hep G2 cells (ATCC HB-8065) were seeded at a density of 2 × 104 cells/well in a
96-well, cell culture-treated microplate. They were incubated for 24 h at 37 ◦C in 5% CO2
to allow the cells to adhere. Cells were then exposed to a 2-fold serial dilution series of
compound 2, in duplicate, giving a final concentration range of 0.2–100 µM. Thioridazine
hydrochloride (Sigma Aldrich) was used as a positive control. The viability of the cells was
determined, after a further 24 h incubation, using CellTiter-Glo (Promega) according to the
manufacturer’s instructions. Inhibition curves were generated to give the concentration of
compound inhibiting 50% of cell viability (IC50) and percentage viability of the cells at the
top tested concentration (100 µM).
4.11. Genome Sequencing
Genomic DNA from strain 28ISP2-46T was purified with a GenElute™ Bacterial
Genomic DNA Kit (Sigma-Aldrich) with some alterations to the manufacturer’s instructions
as follows. 28ISP2-46T was grown for 3 weeks to confluence, in 50 mL ISP2, at 28 ◦C. The
cells were collected using centrifugation and the resulting pellet was frozen at −70 ◦C.
The frozen pellet was crushed using a sterile pestle and mortar. The crushed mass was
transferred to an Eppendorf tube, 200 µL of a lysozyme solution (45 mg/mL) was added,
and the tube was inverted to mix and then incubated at 37 ◦C for 60 min. RNAase solution
(Sigma-Aldrich, R6148) was added (as per the manufacturer’s instructions) and the tube
incubated for 2 min at 20 ◦C. Then Proteinase K (200 µg/mL) and 200 µL lysis buffer
(provided in the kit) were added, the tube inverted 3 times and then incubated at 52 ◦C
for 20 min. Ethanol (100%, 200 µL) was added to the tube, which was inverted to mix. To
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remove the cell debris from the DNA, the tube was centrifuged (5 min, 5000× g). Using a
wide bore pipette the supernatant was transferred to a spin column and the DNA purified
(as per the GenElute™ Bacterial Genomic DNA Kit instructions). The DNA concentration
and purity were ascertained by measuring the absorbance at 260 nm, and any DNA
shearing was identified by gel electrophoresis.
The Bristol Genomics Facility carried out quality assessment and normalisation of
amplicon pools for the genomic DNA sample. Using 1 µg of DNA, a paired-end TruSeq
library was generated, indexed with a Nextera® XT Index Kit and shotgun sequenced on an
Illumina MiSeq, producing 2 × 300 bp reads. The same genomic DNA sample (1 µg) was
also sequenced using a R9 MinION flow cell indexed with the EXP-NBD103 kit (Oxford
Nanopore Technologies, Oxford, UK), following the manufacturer’s instructions.
4.12. Genome Assembly and Mining
Nanopore sequence data were converted from FAST5 data to fastq files using Albacore
1.2.5 for base calling (Oxford Nanopore Technologies, Oxford, UK). Adaptor trimming
and demultiplexing of the Nanopore reads were completed using Porechop (Porechop,
RRID: SCR_016967). Adaptor and quality trimming of the Illumina reads was performed
using Trim Galore v0.4.4 [41] with a PHRED score of 20 as a cut off and default parameters.
Processed reads were either assembled with Unicycler v0.4.6 [16] or a combination of the
long-read assembler Canu 1.8 [42] and the Unicycler pipeline. To maintain lower-length
reads under 1000 bp Canu was run with the flag ‘stopOnReadQuality = false’. The Illumina
only assembly was completed using the IDBA assembler v1.1.3 [43]. Alignment of trimmed
reads against the final assemblies was conducted using Bowtie2 v2.2.9 [44]. The draft
genome was mined using antiSMASH 5.0 (“Antibiotic and Secondary Metabolites Analysis
Shell”) [21]. The phylogenetic tree was produced using the Type Strain Genome Server
(TYGS) [19] and drawn using Interactive Tree of Life (iTOL) [45].
4.13. Genome BGC Comparison
Genomes were annotated using antiSMASH 5.0 [21] with relaxed detection strictness
and all extra features on. The BGCs with similarity to the kosinostatin BGC were manually
annotated using BLASTp to search for homologous proteins for each translated ORF, and
this annotation was extended 20 ORFs upstream and downstream of the antiSMASH-
defined BGC boundaries. ORFs were then aligned with kosinostatin BGC genes with
homologous functions using BLASTp, and annotated as kstA-D, kstRs, kstRg, or kstU ho-
mologs. The nucleotide accession number for the Micromonospora sp. TP-A0468 kosinostatin
BGC is JN038178.1. For the kosinostatin ClusterBLAST [21] relatives, GenBank assembly
accession numbers are as follows: Actinokineospora bangkokensis 44EHW (GCA_001940455.1),
Micromonospora haikouensis DSM 45,626 (GCA_900091595.1), Nocardiopsis alkaliphila YIM
80,379 (GCA_000341005.1), Nocardiopsis valliformis DSM 45,023 (GCA_000340985.1), Strepto-
myces sp. ScaeMP-6W (GCA_900091885.1), Streptomyces sp. SM8 (GCA_000299175.2).
The genomes of the type Ia Micromonospora species were annotated using antiSMASH
5.0 [21] and manually inspected for BGCs with significant similarity to each BGC of strain
28ISP2-46T.
For the group Ia Micromonospora species, GenBank assembly accession numbers are
as follows: Micromonospora aurantiaca ATCC 27,029 (GCA_000145235.1), Micromonospora
auratinigra DSM 44,815 (GCA_900089595.1), Micromonospora chaiyaphumensis DSM 45,246
(GCA_900091435.1), Micromonospora chalcea DSM 43,026 (GCA_002926165.1), Micromonospora
chersina DSM 44,151 (GCA_900091475.1), Micromonospora humi DSM 45,647 (GCA_900090105.1),
Micromonospora marina DSM 45,555 (GCA_900091565.1), Micromonospora sediminicola DSM
45,794 (GCA_900089585.1) and Micromonospora tulbaghiae CNY-010 (GCA_003612775.1).
Supplementary Materials: The following are available online at https://www.mdpi.com/1660-3
397/19/2/105/s1. Supplementary Section S1: LC–MS analysis of the extract from 28ISP2-28T; Sup-
plementary Section S2: NMR chemical shifts of (2) (isoquinocycline B); Supplementary Section S3:
16S rRNA gene sequencing of 28ISP2-46T; Figure S1: Photographs of sponge sample B0078 retrieved
Mar. Drugs 2021, 19, 105 17 of 19
from the Knipovich seamount; Figure S2: Small-volume liquid culture antibiotic activity assay of
28ISP2-28T; Figure S3: 1H NMR spectrum of isoquinocycline B (2, CD3OD, 500 MHz); Figure S4:
13C NMR spectrum of isoquinocycline B (2, CD3OD, 125 MHz); Figure S5: 1H-1H COSY spec-
trum of spectrum of isoquinocycline B (2); Figure S6: HSQC spectrum of isoquinocycline B (2);
Figure S7: HMBC spectrum of isoquinocycline B (2); Figure S8: The predicted function of KstB7 in
pyrrolopyrrole biosynthesis according to Ma et al. 2013 [22]; Figure S9: The WebMGA COG families
and the fractional coverage of each COG family for ORFs in the Micromonospora sp. 28ISP2-46T
genome; Table S1: Bacterial strains used in this study; Table S2: Sequence identity comparison of the
28ISP2-46T 16S rRNA gene sequence with the most closely related strains; Table S3: BCG comparison
of Micromonospora group Ia strains with strain 28ISP2-46T; Table S4: The NCBI Prokaryotic Genome
Annotation Pipeline Annotation data for the strain 28ISP2-46T genome assembly.
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